
The FDA granted accelerated approval to the first plasmid DNA-based immunotherapy for adults with recurrent respiratory papillomatosis (RRP).
Supplements and Featured Publications
over 27 years ago
Participating Facultyover 27 years ago
Introductionover 27 years ago
Issues in Vascular Complianceover 27 years ago
Selected Abstractsover 27 years ago
Bibliography





